BR0115301A - Use of a selective norepinephrine reuptake inhibitor - Google Patents

Use of a selective norepinephrine reuptake inhibitor

Info

Publication number
BR0115301A
BR0115301A BR0115301-3A BR0115301A BR0115301A BR 0115301 A BR0115301 A BR 0115301A BR 0115301 A BR0115301 A BR 0115301A BR 0115301 A BR0115301 A BR 0115301A
Authority
BR
Brazil
Prior art keywords
selective norepinephrine
norepinephrine reuptake
reuptake inhibitor
selective
inhibitor
Prior art date
Application number
BR0115301-3A
Other languages
Portuguese (pt)
Inventor
Holly Read Thomasson
David Michelson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR0115301A publication Critical patent/BR0115301A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"USO DE UM INIBIDOR SELETIVO DA RECAPTAçãO DE NOREPINEFRINA". Inibidores seletivos da recaptação de norepinefrina são usados para tratar distúrbios de ansiedade, especialmente distúrbios obsessivo-compulsivos."USE OF A SELECTIVE NOREPINEPHRINE RECAPTATION INHIBITOR". Selective norepinephrine reuptake inhibitors are used to treat anxiety disorders, especially obsessive-compulsive disorders.

BR0115301-3A 2000-11-15 2001-11-06 Use of a selective norepinephrine reuptake inhibitor BR0115301A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24901000P 2000-11-15 2000-11-15
US26536201P 2001-01-31 2001-01-31
PCT/US2001/027801 WO2002040006A2 (en) 2000-11-15 2001-11-06 Treatment of anxiety disorders

Publications (1)

Publication Number Publication Date
BR0115301A true BR0115301A (en) 2004-12-14

Family

ID=26939750

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0115301-3A BR0115301A (en) 2000-11-15 2001-11-06 Use of a selective norepinephrine reuptake inhibitor

Country Status (16)

Country Link
EP (1) EP1395253A2 (en)
JP (1) JP2004529073A (en)
KR (1) KR20030051812A (en)
CN (1) CN1822825A (en)
AU (1) AU2002217757A1 (en)
BR (1) BR0115301A (en)
CA (1) CA2426069A1 (en)
CZ (1) CZ20031339A3 (en)
EA (1) EA200300567A1 (en)
HR (1) HRP20030384A2 (en)
IL (1) IL155874A0 (en)
MX (1) MXPA03004190A (en)
NO (1) NO20032156D0 (en)
PL (1) PL366119A1 (en)
SK (1) SK5422003A3 (en)
WO (1) WO2002040006A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20032380A3 (en) * 2001-03-06 2004-03-17 Eli Lilly And Company Inhibitor of monoamine uptake
CN1674907A (en) * 2002-08-14 2005-09-28 法玛西亚普强责任有限公司 Use of reboxetine for the treatment of hot flashes
GB0309440D0 (en) * 2003-04-25 2003-06-04 Lilly Co Eli Quinolone derivatives
WO2004103356A2 (en) * 2003-05-15 2004-12-02 Eli Lilly And Company Treatment of emotional dysregulation
KR20060121178A (en) * 2003-12-12 2006-11-28 일라이 릴리 앤드 캄파니 Selective norephinephrine reuptake inhibitors for the treatment of hot flashes, impulse control disorders and personality change due to a general medical condition
WO2009089479A2 (en) 2008-01-09 2009-07-16 Mayo Foundation For Medical Education And Research Inhibiting neurotransmitter reuptake
US20120220665A1 (en) * 2009-11-03 2012-08-30 Mayo Foundation For Medical Education And Research Inhibiting Neurotransmitter Reuptake
WO2011056788A2 (en) * 2009-11-03 2011-05-12 Mayo Foundation For Medical Education And Research Inhibiting neurotransmitter reuptake
WO2014159251A2 (en) 2013-03-14 2014-10-02 Mayo Foundation For Medical Education And Research Inhibiting neurotransmitter reuptake
JP2022519541A (en) * 2019-02-01 2022-03-24 ホフマン・テクノロジーズ・エルエルシー Compositions and Methods for Treating Anxiety-Related Disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2931997A (en) * 1996-05-07 1997-11-26 Merck & Co., Inc. Treatment of mood disorders with a growth hormone secretagogue
IT1305322B1 (en) * 1998-04-23 2001-05-04 Pharmacia & Upjohn Spa Use of reboxetine for treating obsessive compulsive disorder and panic disorder
ES2246485T3 (en) * 1999-07-01 2006-02-16 PHARMACIA & UPJOHN COMPANY LLC (S, S) -REBOXETINE TO TREAT INCONTINENCE.

Also Published As

Publication number Publication date
IL155874A0 (en) 2003-12-23
CZ20031339A3 (en) 2003-10-15
CN1822825A (en) 2006-08-23
NO20032156L (en) 2003-05-13
WO2002040006A3 (en) 2003-12-24
AU2002217757A1 (en) 2002-05-27
JP2004529073A (en) 2004-09-24
MXPA03004190A (en) 2003-09-22
HRP20030384A2 (en) 2003-08-31
CA2426069A1 (en) 2002-05-23
WO2002040006A2 (en) 2002-05-23
EA200300567A1 (en) 2004-10-28
EP1395253A2 (en) 2004-03-10
KR20030051812A (en) 2003-06-25
NO20032156D0 (en) 2003-05-13
PL366119A1 (en) 2005-01-24
SK5422003A3 (en) 2003-12-02

Similar Documents

Publication Publication Date Title
BR0112786A (en) Non-Steroidal Inhibitors of Inflammation
IT1317757B1 (en) METHOD FOR THE PREPARATION OF HYDROGENATED HYDROCARBONS.
NO20016406L (en) High selective reuptake inhibitors for norepinephrine
MY134110A (en) Combinations of reboxetine and neuroleptic agents
RS20050392A (en) Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor
TR200000755T2 (en) Treatment of anti-oppositional disorder.
DZ3192A1 (en) Diaryl ether derivatives used as monoamine reuptake inhibitors.
BR0114903A (en) 7-azaindoles, their application as phosphodiesterase 4 inhibitors and processes for their preparation
SE0100901D0 (en) New composition
BR0112292A (en) Compound, pharmaceutical composition, method for treating or preventing thromboembolic disorders and use of a compound
IS6003A (en) Monoamine reuptake inhibitors for the treatment of central nervous system disorders
DK1506185T3 (en) Compounds and their use as 5-HT inhibitors
NO20030842D0 (en) Phenoxybenzylamine derivatives as selective serotonin reuptake inhibitors
DE60206164D1 (en) TRISUBSTITUTED-N - ((1S) -1,2,3,4-TETRAHYDRO-1-NAPHTHALENYL) BENZAMIDES INHIBITING P2X3 AND P2X2 / 3 CONTAINING RECEPTORS
BR0115301A (en) Use of a selective norepinephrine reuptake inhibitor
BR0213581A (en) Use of a selective norepinephrine reuptake inhibitor
WO2001066101A3 (en) Treatment of psoriasis
RS51534B (en) NEW ASSOCIATION OF AN If SINUSOIDAL CURRENT INHIBITOR AND A CALCIUM CHANNEL-BLOCKING AGENT, AND PHARMACEUTICAL INGREDIENTS CONTAINING SAID ASSOCIATION
BR0114380A (en) 1-Aminobutan-3-ol-substituted derivatives
NO20061425L (en) The combination of a serotonin reuptake inhibitor and loxapine
DK1455770T3 (en) Use of norepinephrine uptake inhibitors for the treatment of tic disorders
PT1161239E (en) 3-CYCLOPROPYLMETHOXY-4-DIFLUOROMETHOXY-N- (3,5-DICHLOROPYRID-4-YL) -BENZAMIDE FOR THE TREATMENT OF MULTIPLE SCLEROSIS
UY26556A1 (en) CALCILITE COMPOUNDS
DK1177191T3 (en) Substituted benzimidazoles, preparation and use thereof as agents for the control of parasitic protozoa
BR0101437A (en) Method for preparing a cyclopropene

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 1964 DE 26/08/2008 E CONSIDERANDO A AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS.